Related Experiment Video
Updated: Sep 3, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Renal cell carcinoma detection and systemic therapy with tumour-affine gallium-67 and with yttrium-90 citrate
S K Shukla1, G S Limouris, R Cusumano
1Servizio di Medicina Nucleare, Ospedale S. Eugenio, Roma, Italy.
Background:
There have been no major advances in the systemic detection of renal cell carcinoma (RCC) and its unpredictable metastases. Surgery, thus, remains the mainstay of the curative treatment for the localized disease. The propose of the present study has been to systemically detect and treat advanced RCC respectively with Ga-67 and Y-90 radiopharmaceuticals containing tumour-affine species.
Patients And Methods:
Thirty-three RCC patients were imaged with Tc-99m-MDP and then with Ga-67 citrate solution in order to detect RCC and its metastases. Yttrium-90 citrate solution, containing the radionuclide species chromatographically and electrophoretically identical to those in RCC-affine Ga-67 solution, was administered i.v. for systemic therapy of advanced RCC. Total-body distribution of Y-90 was studied with a gamma-camera equipped with an ultra-high-sensitivity collimator. The efficacy of the therapy was studied by the clinical condition of the patient and by the total-body scintigraphic imaging with Tc-99m-MDP and with Ga-67 citrate solution.
Results:
Ga-67 detects RCC bone metastases better than Tc-99m-MDP. Systemic therapy of RCC metastasized to bones, lung and brain was obtained with RCC-affine Y-90 citrate solution.
Conclusions:
Third group metal radionuclides, Ga-67 and Y-90, detect and treat advanced RCC.
Insights
Gallium-67 (Ga-67) and Yttrium-90 (Y-90) radiopharmaceuticals show promise for detecting and treating advanced renal cell carcinoma (RCC) and its metastases.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Therapy
Background:
- Limited advances in systemic detection of renal cell carcinoma (RCC) and its metastases.
- Surgery remains the primary curative treatment for localized RCC.
- Need for effective systemic detection and treatment of advanced RCC.
Purpose of the Study:
- To systemically detect advanced RCC using Ga-67.
- To systemically treat advanced RCC using Y-90 radiopharmaceuticals.
- To evaluate the efficacy of Ga-67 and Y-90 in RCC detection and treatment.
Main Methods:
- 33 RCC patients underwent imaging with Tc-99m-MDP and Ga-67 citrate.
- Ga-67 citrate solution was used for RCC and metastasis detection.
- Y-90 citrate solution, identical to Ga-67 in tumor-affine species, was administered for systemic therapy.
- Y-90 distribution studied with gamma-camera; therapy efficacy assessed via clinical condition and scintigraphy.
Main Results:
- Ga-67 demonstrated superior detection of RCC bone metastases compared to Tc-99m-MDP.
- Systemic therapy with Y-90 citrate solution was effective for RCC metastasized to bone, lung, and brain.
Conclusions:
- Third-group metal radionuclides, Ga-67 and Y-90, are effective in detecting and treating advanced RCC.
- Ga-67 and Y-90 offer a potential systemic approach for advanced renal cell carcinoma.
